Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma

In order to facilitate long-term treatment decisions, we aimed to define biomarkers defining the probability of receiving second-line (SL) targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC) based on their characteristics present at first-line TT initiation. We analysed 152...

Descripción completa

Detalles Bibliográficos
Autores principales: Chrom, Pawel, Kawecki, Maciej, Stec, Rafal, Bodnar, Lubomir, Szczylik, Cezary, Czarnecka, Anna M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940724/
https://www.ncbi.nlm.nih.gov/pubmed/29737510
http://dx.doi.org/10.1007/s12032-018-1148-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940724/
https://www.ncbi.nlm.nih.gov/pubmed/29737510
http://dx.doi.org/10.1007/s12032-018-1148-x

Ejemplares similares